拒绝二尖瓣介入治疗的患者的表型聚类分析:对未来经导管技术的影响。

IF 6.7 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS
Sebastian Ludwig, Augustin Coisne, Kenza Hamzi, Walid Ben Ali, Andrea Scotti, Benedikt Koell, Alison Duncan, Raj Makkar, Mariama Akodad, Sabine Bleiziffer, Georg Nickenig, Tsuyoshi Kaneko, Hendrik Ruge, Matti Adam, Lars Sondergaard, Gry Dahle, Maurizio Taramasso, Thomas Walther, Joerg Kempfert, Jean-François Obadia, Omar Chehab, Gilbert H L Tang, Sachin Goel, Neil Fam, Paolo Denti, Fabien Praz, Ralph Stephan von Bardeleben, Jörg Hausleiter, Azeem Latib, Lenard Conradi, Thomas Modine, Théo Pezel, Juan F Granada
{"title":"拒绝二尖瓣介入治疗的患者的表型聚类分析:对未来经导管技术的影响。","authors":"Sebastian Ludwig, Augustin Coisne, Kenza Hamzi, Walid Ben Ali, Andrea Scotti, Benedikt Koell, Alison Duncan, Raj Makkar, Mariama Akodad, Sabine Bleiziffer, Georg Nickenig, Tsuyoshi Kaneko, Hendrik Ruge, Matti Adam, Lars Sondergaard, Gry Dahle, Maurizio Taramasso, Thomas Walther, Joerg Kempfert, Jean-François Obadia, Omar Chehab, Gilbert H L Tang, Sachin Goel, Neil Fam, Paolo Denti, Fabien Praz, Ralph Stephan von Bardeleben, Jörg Hausleiter, Azeem Latib, Lenard Conradi, Thomas Modine, Théo Pezel, Juan F Granada","doi":"10.1093/ehjci/jeaf141","DOIUrl":null,"url":null,"abstract":"<p><strong>Aims: </strong>Although several treatment options are available for patients with severe mitral regurgitation (MR), a significant proportion of patients remain ineligible for any mitral valve (MV) intervention. We aimed to analyze the phenotypic characteristics of surgical high-risk patients ineligible for MV interventions using an unsupervised phenotypic clustering approach.</p><p><strong>Methods and results: </strong>Between 2014 and 2022, the CHOICE-MI registry included 984 patients with MR undergoing screening for transcatheter mitral valve replacement at 33 international sites. For this study, only patients with screening failure receiving medical therapy alone were included. Patients receiving transcatheter or surgical treatment were excluded. A cluster analysis using K-means was performed on baseline clinical, demographic, and imaging variables to identify different patient phenotypes. Among 284 patients with MR (77.4±8.82 years, 56.0% female, EuroSCORE II: 6.6±5.8%) considered ineligible for any MV intervention, two clinically distinct phenogroups (PG) were identified using unsupervised hierarchical clustering of principal components. PG1: elderly women with primary MR, preserved left ventricular function, and annular calcification; and PG2: patients with secondary MR, advanced heart failure, and high prevalence of comorbidities. One-year all-cause mortality did not differ between the phenogroups (PG1: 21.4%, PG2: 23.4%, p=0.89). Predictors of mortality were albumin, renal function, extracardiac arteriopathy for PG1, and albumin, coronary artery disease, and prior myocardial infarction for PG2.</p><p><strong>Conclusions: </strong>This study identified two major subgroups among patients ineligible for mitral interventions showing profound differences in clinical and anatomical profiles. Identifying these factors may drive technological evolution to address the unmet clinical need for therapeutic options in MR patients.</p><p><strong>Clinicaltrials.gov identifier: </strong>NCT04688190 (CHOICE-MI Registry).</p>","PeriodicalId":12026,"journal":{"name":"European Heart Journal - Cardiovascular Imaging","volume":" ","pages":""},"PeriodicalIF":6.7000,"publicationDate":"2025-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Phenotypic Clustering Analysis of Patients Rejected for Mitral Valve Interventions: Implications for Future Transcatheter Technologies.\",\"authors\":\"Sebastian Ludwig, Augustin Coisne, Kenza Hamzi, Walid Ben Ali, Andrea Scotti, Benedikt Koell, Alison Duncan, Raj Makkar, Mariama Akodad, Sabine Bleiziffer, Georg Nickenig, Tsuyoshi Kaneko, Hendrik Ruge, Matti Adam, Lars Sondergaard, Gry Dahle, Maurizio Taramasso, Thomas Walther, Joerg Kempfert, Jean-François Obadia, Omar Chehab, Gilbert H L Tang, Sachin Goel, Neil Fam, Paolo Denti, Fabien Praz, Ralph Stephan von Bardeleben, Jörg Hausleiter, Azeem Latib, Lenard Conradi, Thomas Modine, Théo Pezel, Juan F Granada\",\"doi\":\"10.1093/ehjci/jeaf141\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Aims: </strong>Although several treatment options are available for patients with severe mitral regurgitation (MR), a significant proportion of patients remain ineligible for any mitral valve (MV) intervention. We aimed to analyze the phenotypic characteristics of surgical high-risk patients ineligible for MV interventions using an unsupervised phenotypic clustering approach.</p><p><strong>Methods and results: </strong>Between 2014 and 2022, the CHOICE-MI registry included 984 patients with MR undergoing screening for transcatheter mitral valve replacement at 33 international sites. For this study, only patients with screening failure receiving medical therapy alone were included. Patients receiving transcatheter or surgical treatment were excluded. A cluster analysis using K-means was performed on baseline clinical, demographic, and imaging variables to identify different patient phenotypes. Among 284 patients with MR (77.4±8.82 years, 56.0% female, EuroSCORE II: 6.6±5.8%) considered ineligible for any MV intervention, two clinically distinct phenogroups (PG) were identified using unsupervised hierarchical clustering of principal components. PG1: elderly women with primary MR, preserved left ventricular function, and annular calcification; and PG2: patients with secondary MR, advanced heart failure, and high prevalence of comorbidities. One-year all-cause mortality did not differ between the phenogroups (PG1: 21.4%, PG2: 23.4%, p=0.89). Predictors of mortality were albumin, renal function, extracardiac arteriopathy for PG1, and albumin, coronary artery disease, and prior myocardial infarction for PG2.</p><p><strong>Conclusions: </strong>This study identified two major subgroups among patients ineligible for mitral interventions showing profound differences in clinical and anatomical profiles. Identifying these factors may drive technological evolution to address the unmet clinical need for therapeutic options in MR patients.</p><p><strong>Clinicaltrials.gov identifier: </strong>NCT04688190 (CHOICE-MI Registry).</p>\",\"PeriodicalId\":12026,\"journal\":{\"name\":\"European Heart Journal - Cardiovascular Imaging\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":6.7000,\"publicationDate\":\"2025-05-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Heart Journal - Cardiovascular Imaging\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1093/ehjci/jeaf141\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Heart Journal - Cardiovascular Imaging","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/ehjci/jeaf141","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

摘要

目的:尽管对于严重二尖瓣返流(MR)患者有几种治疗选择,但很大比例的患者仍然不适合任何二尖瓣(MV)干预。我们的目的是使用无监督表型聚类方法分析不适合MV干预的手术高危患者的表型特征。方法和结果:2014年至2022年间,CHOICE-MI登记包括984例MR患者,在33个国际站点接受经导管二尖瓣置换术筛查。本研究仅纳入筛查失败的患者单独接受药物治疗。排除接受经导管或手术治疗的患者。使用K-means对基线临床、人口统计学和影像学变量进行聚类分析,以确定不同的患者表型。284例MR患者(77.4±8.82岁,56.0%女性,EuroSCORE II: 6.6±5.8%)被认为不适合任何MV干预,使用主成分的无监督分层聚类确定了两个临床不同的表型组(PG)。PG1:原发性MR,左心室功能保留,环形钙化的老年女性;PG2:继发性MR,晚期心力衰竭,合并症患病率高的患者。一年全因死亡率在表型组之间没有差异(PG1: 21.4%, PG2: 23.4%, p=0.89)。死亡率的预测因子是白蛋白、肾功能、心外动脉病变(PG1)和白蛋白、冠状动脉疾病和既往心肌梗死(PG2)。结论:本研究确定了不适合二尖瓣介入治疗的患者中的两个主要亚组,它们在临床和解剖特征上存在巨大差异。识别这些因素可能会推动技术发展,以解决MR患者未满足的治疗选择的临床需求。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Phenotypic Clustering Analysis of Patients Rejected for Mitral Valve Interventions: Implications for Future Transcatheter Technologies.

Aims: Although several treatment options are available for patients with severe mitral regurgitation (MR), a significant proportion of patients remain ineligible for any mitral valve (MV) intervention. We aimed to analyze the phenotypic characteristics of surgical high-risk patients ineligible for MV interventions using an unsupervised phenotypic clustering approach.

Methods and results: Between 2014 and 2022, the CHOICE-MI registry included 984 patients with MR undergoing screening for transcatheter mitral valve replacement at 33 international sites. For this study, only patients with screening failure receiving medical therapy alone were included. Patients receiving transcatheter or surgical treatment were excluded. A cluster analysis using K-means was performed on baseline clinical, demographic, and imaging variables to identify different patient phenotypes. Among 284 patients with MR (77.4±8.82 years, 56.0% female, EuroSCORE II: 6.6±5.8%) considered ineligible for any MV intervention, two clinically distinct phenogroups (PG) were identified using unsupervised hierarchical clustering of principal components. PG1: elderly women with primary MR, preserved left ventricular function, and annular calcification; and PG2: patients with secondary MR, advanced heart failure, and high prevalence of comorbidities. One-year all-cause mortality did not differ between the phenogroups (PG1: 21.4%, PG2: 23.4%, p=0.89). Predictors of mortality were albumin, renal function, extracardiac arteriopathy for PG1, and albumin, coronary artery disease, and prior myocardial infarction for PG2.

Conclusions: This study identified two major subgroups among patients ineligible for mitral interventions showing profound differences in clinical and anatomical profiles. Identifying these factors may drive technological evolution to address the unmet clinical need for therapeutic options in MR patients.

Clinicaltrials.gov identifier: NCT04688190 (CHOICE-MI Registry).

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
European Heart Journal - Cardiovascular Imaging
European Heart Journal - Cardiovascular Imaging CARDIAC & CARDIOVASCULAR SYSTEMS-
CiteScore
11.60
自引率
9.70%
发文量
708
审稿时长
4-8 weeks
期刊介绍: European Heart Journal – Cardiovascular Imaging is a monthly international peer reviewed journal dealing with Cardiovascular Imaging. It is an official publication of the European Association of Cardiovascular Imaging, a branch of the European Society of Cardiology. The journal aims to publish the highest quality material, both scientific and clinical from all areas of cardiovascular imaging including echocardiography, magnetic resonance, computed tomography, nuclear and invasive imaging. A range of article types will be considered, including original research, reviews, editorials, image focus, letters and recommendation papers from relevant groups of the European Society of Cardiology. In addition it provides a forum for the exchange of information on all aspects of cardiovascular imaging.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信